Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Theraprutic Effect of New Drugs for Hepatocellular Carcinoma

NCT07233759 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT07233759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07233759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Theraprutic Effect of New Drugs for Hepatocellular Carcinoma
Lead sponsor
National Taiwan University Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
January 31, 2023
Completion date
December 31, 2026
Enrollment
2,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atezolizumab, lenvatinib, liver cancer, pembrolizumab